June 23, 2018 : Issue #943

• Amazing Outcomes with Combination Therapy of GLP-1 Receptor Agonist and SGLT2 Inhibitors
• Post-Surgery Outcomes in Patients with Diabetes and Elevated HbA1c
• A New Method of Preventing Exercise-Induced Hypoglycemia in Type 1 Diabetes
• The “REAL” Diabetes Study Shows How Occupational Therapy Can Help Young Adults Better Manage Their Diabetes
• Features That Predispose Patients with T2DM To Severe Hypoglycemia
• Being Overweight in Childhood Increases Risk of Diabetes in Adulthood?

The ADA Scientific sessions are underway in Orlando and Steve Freed and Joy Pape, along with our two interns Kaytie and Kennen, and guest Michele Laine, ARNP, CDE, are there to cover all the latest in diabetes, and interview the thought leaders on where diabetes care is and where it is going over the next 1-3 years.

Please check out our Newsflashes to see what we have learned already and then take a look at our feature article by our Doctor of Pharmacy Candidate, Kennen Munoz Munoz, as he delivers info on one of the hottest topics of discussion, the use of a GLP-1 agonist along with an SGLT-2 Inhibitor.

As Barney Stinson once said on the hit show How I Met Your Mother: “It’s gonna be legen — wait for it … and I hope you’re not lactose-intolerant ’cause the second half of that word is — dary!”

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

The FDA approved the first long-term implantable continuous glucose monitor (CGM) on Friday, the maker Senseonics announced.  The Eversense CGM System features an implantable glucose sensor that can remain in place for up to 3 months, beating out the usual wear time of 3-10 days for many of the other CGMs currently available.

Coming Soon! Watch for our Special Edition of Breaking News from the ADA 78th Scientific Sessions with interviews from the major presenters.

Would you feel comfortable using a combination treatment of a GLP-1 receptor agonist and a SGLT-2 inhibitor for a patient who has not reached goal? Follow the link to respond.

FDA approval was based on positive results from a pediatric clinical trial, which demonstrated the safety of the MiniMed 670G system in this younger patient population. The MiniMed 670G system is commercially available for immediate shipment to patients interested in transitioning to the system.

GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several naturally occurring incretin compounds that affect the body after they are released from the gut during digestion. By binding and activate GLP-1 receptors, GLP-1 agonists, and endogenous GLP-1 are capable to reduce blood glucose levels helping T2DM patients to reach a glycemic control. Download the chart of currently available GLP-1 drugs.

You are concerned about Mr. Carlson’s cigarette use because cigarette smoking has been shown to have multiple physiological impacts on health. Which one of the following statements regarding smoking and type 2 diabetes is true?

A. It equally affects all-cause mortality in individuals with and without diabetes
B. In individuals with diabetes, it causes more rapid progression to micro- and macroalbuminuria
C. It has not been linked to worsening glycemic control
D. The use of bupropion in contraindicated in diabetes

Follow the link to see the answer,

The different mechanisms of action of these two drugs make them an excellent combination in the treatment of patients with type 2 diabetes mellitus (T2DM).

Investigation into the effect of surgery, from mortality to length of hospital stay, on patients who have diabetes with consistently high blood glucose.

Mini-dose glucagon might be a better option for treating exercise-induced hypoglycemia than carbohydrate ingestion or insulin dose reduction.

Study reveals how implementing occupational therapy strategies can help patients achieve glycemic goals.

Study describes patient characteristics that place patients with type 2 diabetes at increased risk for severe hypoglycemia.

Childhood overweight is associated with an increased risk of type 2 diabetes in adulthood.

Quote of the Week!

“A cloudy day is no match for a sunny disposition.”

…William Arthur Ward

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:

Kaytie A. Weierstahl, Pharm.D. Candidate, LECOM School of Pharmacy

Kennen Munoz Munoz, Pharm. D. Candidate 2019, LECOM School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com